Clinical Trial Update: Nivolumab and Pembrolizumab Dose Optimisation in Solid Tumours With CURATE.AI Platform and Sequential ctDNA Measurements [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update evaluating dose optimization of nivolumab and pembrolizumab in solid tumors using the CURATE.AI platform with sequential ctDNA measurement…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Solid Tumor

Drugs mentioned

• Pembrolizumab (pembrolizumab)
• nivolumab (nivolumab)

Snippet

Sponsor: National University Hospital, Singapore | Conditions: Solid Tumor | Phase 1, Phase 2 | Status: UNKNOWN